

Workshop on Public-Private Partnership Responses to COVID-19 and Future Pandemics

Speaker Biographies

Arnaud Bernaert, M.B.A., dedicated his prolific career to strategy, partnerships, M&A and Healthcare policy matters. He also published extensively on those themes and received significant media coverage. This he has done first as a senior executive in multinational organizations such as Baxter and Philips Healthcare, then as the Global Head for Health and Healthcare Industries at the World Economic Forum. Arnaud Bernaert has a unique understanding of Global Health and Healthcare challenges. He also maintains deep personal connections within a unique network of industry CEO's, policy makers, regulators, heads of international organizations and civil society leaders. As a member of the Executive Committee of the World Economic Forum, Mr. Bernaert has launched defining public private coalitions in fields as diverse as epidemics preparedness, vaccines and antibiotic innovation, value based healthcare, precision medicine regulations, access to primary care, payment reforms, and healthcare IT, just to name a few. On such matters and many others, he also addressed—as key note speaker, panelist, moderator or knowledge expert—the participants of the most prestigious global healthcare gatherings in Davos, UNGA, Forbes conferences, World Health Assembly week, World Health summit and many other conferences. Mr. Bernaert received his M.B.A. from HEC.

Beth Cameron, Ph.D., is NTI's Vice President for Global Biological Policy and Programs. Dr. Cameron previously served as the senior director for global health security and biodefense on the White House National Security Council (NSC) staff, where she was instrumental in developing and launching the Global Health Security Agenda and addressed homeland and national security threats surrounding biosecurity and biosafety, biodefense, emerging infectious disease threats, biological select agents and toxins, dual-use research, and bioterrorism. From 2010-2013, Dr. Cameron served as office director for Cooperative Threat Reduction (CTR) and senior advisor for the Assistant Secretary of Defense for nuclear, chemical and biological defense programs. In this role, she oversaw implementation of the geographic expansion of the Nunn-Lugar CTR program. For her work, she was awarded the Office of the Secretary of Defense Medal for Exceptional Civilian Service. From 2003-2010, Dr. Cameron oversaw expansion of Department of State Global Threat Reduction programs and supported the expansion and extension of the Global Partnership Against the Spread of Weapons and Materials of Mass Destruction, a multilateral framework to improve global CBRN security. Dr. Cameron served as an American Association for the Advancement of Science (AAAS) fellow in the health policy office of Senator Edward M. Kennedy where she worked on the Patients' Bill of Rights, medical privacy, and legislation to improve the quality of cancer care. From 2001-2003, she served as a manager of policy research for the American Cancer Society. Dr. Cameron holds a Ph.D. in Biology from the Human Genetics and Molecular Biology Program at the Johns Hopkins University and a B.A. in Biology from the University of Virginia. Cameron is a member of the Council on Foreign Relations.

Brenda D. Colatrella, M.B.A., is Associate Vice-President, Corporate Responsibility at Merck & Co., Inc., a central function that coordinates the development, implementation and reporting of Merck's global corporate responsibility approach on environmental, social and governance issues in alignment with the company's business strategy. She is also responsible for Merck's global health patient assistance programs and partnerships that help to expand access to medicines, vaccines and quality health care. Ms. Colatrella serves as President of the Merck Foundation, a U.S. based private charitable foundation,

funded entirely by Merck, that is Merck's chief source of funding support for qualified charitable organizations, as well as President of the Merck Patient Assistance Program which provides free Merck medications and adult vaccines to eligible individuals in the U.S. who need specific Merck medicines, but do not have access to them through insurance coverage and who cannot afford to pay for them. She has written several articles on product donations, best practices in public-private partnerships, the role of the private sector in global health, and the importance of effective environmental, social and governance (ESG) management and reporting. Ms. Colatrella received her B.A. from Muhlenberg College, summa cum laude, Phi Beta Kappa, and her M.B.A. from New York University's Stern School of Business, where she was the recipient of the Dean's Award.

Victor J. Dzau, M.D., is the President of the National Academy of Medicine (NAM), formerly the Institute of Medicine (IOM). In addition, he serves as Chair of the IOM Division Committee of the National Academies of Sciences, Engineering, and Medicine. He is Chancellor Emeritus and James B. Duke Professor of Medicine at Duke University and the past President and CEO of the Duke University Health System. Previously, Dr. Dzau was the Hersey Professor of Theory and Practice of Medicine and Chairman of Medicine at Harvard Medical School's Brigham and Women's Hospital, as well as Chairman of the Department of Medicine at Stanford University. Dr. Dzau has made a significant impact on medicine through his seminal research in cardiovascular medicine and genetics, his pioneering of the discipline of vascular medicine, and his leadership in health care innovation. His important work on the renin angiotensin system (RAS) paved the way for the contemporary understanding of RAS in cardiovascular disease and the development of RAS inhibitors as widely used, lifesaving drugs. Dr. Dzau also pioneered gene therapy for vascular disease, and his recent work on stem cell paracrine mechanisms and the use of microRNA in direct reprogramming provides novel insight into stem cell biology and regenerative medicine. In his role as a leader in health care, Dr. Dzau has led efforts in health care innovation. His vision is for academic health sciences centers to lead the transformation of medicine through innovation, translation, and globalization. Leading this vision at Duke, he and his colleagues developed the Duke Translational Medicine Institute, the Duke Global Health Institute, the Duke-National University of Singapore Graduate Medical School, and the Duke Institute for Health Innovation. These initiatives create a seamless continuum from discovery and translational sciences to clinical care, and they promote transformative innovation in health. As one of the world's preeminent academic health leaders, Dr. Dzau advises governments, corporations, and universities worldwide. He has been a member of the Council of the IOM and the Advisory Committee to the Director of the National Institutes of Health (NIH), as well as Chair of the NIH Cardiovascular Disease Advisory Committee and the Association of Academic Health Centers. He served on the Governing Board of the Duke-National University of Singapore Graduate Medical School and the Board of Health Governors of the World Economic Forum and chaired its Global Agenda Council on Personalized and Precision Medicine. He also served as the Senior Health Policy Advisor to Her Highness Sheikha Moza (Chair of the Qatar Foundation). Currently, he is a member of the Board of Directors of the Singapore Health System, the Expert Board of the Imperial College Health Partners, UK, and the International Advisory Board of the Biomedical Science Council of Singapore. In 2011, he led a partnership between Duke University, the World Economic Forum, and McKinsey, and he founded the International Partnership for Innovative Healthcare Delivery and currently chairs its Board of Directors. Among his honors and recognitions are the Gustav Nylin Medal from the Swedish Royal College of Medicine; the Max Delbrück Medal from Humboldt University, Charité, and the Max Planck Institute; the Commemorative Gold Medal from the Ludwig Maximilian University of Munich; the Inaugural Hatter Award from the Medical Research Council

of South Africa; the Polzer Prize from the European Academy of Sciences and Arts; the Novartis Award for Hypertension Research; the Distinguished Scientist Award from the American Heart Association (AHA); and the AHA Research Achievement Award for his contributions to cardiovascular biology and medicine. Recently, he was awarded the Public Service Medal by the President of Singapore. He has received eight honorary doctorates.

Chris Elias, M.D., M.P.H., is the president of the Global Development Division, where he leads the foundation's efforts in a diverse range of program areas aimed at finding creative new ways to ensure solutions and products get into the hands of people in poor countries who need them most. Focusing on areas with the potential for high-impact, sustainable solutions that can reach hundreds of millions of people, Dr. Elias oversees Global Development's portfolio in Emergency Response; Family Planning; Maternal, Newborn & Child Health; Nutrition; Polio Eradication; and Vaccine Delivery. A common theme of these programs is innovative and integrated delivery, including an emphasis on strengthening of primary health care systems. Dr. Elias's professional background is in public health and medicine. Prior to joining the Gates Foundation in February 2012, he worked in various positions and countries for international nonprofit organizations, most recently serving as the president and CEO of PATH, an international, nonprofit organization dedicated to improving the health of people around the world by advancing technologies, strengthening systems, and encouraging healthy behaviors.

Trevor Gunn, Ph.D., is Vice President of International Relations for Medtronic, the world's largest medical technology company. Dr. Gunn was formerly long-time Director of the Commerce Department's Business Information Service for the Newly Independent States (BISNIS) the clearinghouse for U.S. Government information for doing business in the former Soviet Union. He has served continuously for the past 26 years, and currently serves as Adjunct Professor at CERES/School of Foreign Service, Georgetown University. He has worked with the Chamber of Commerce of Southern Sweden, Dover Elevator Corporation (now ThyssenKrupp of Germany), International Executive Service Corps and on the staffs of the former San Francisco Mayor and two U.S. Senators from California. Dr. Gunn is the Founder and Chairman of the USA Healthcare Alliance (USAHA). He sits on the U.S. State Department's Stakeholder Advisory Board on the OECD Guidelines on Corporate Social Responsibility; is an official Advisor to the Office of the US Trade Representative (USTR) in the "Industry Trade Advisory" system of the U.S. Government. Dr. Gunn chairs the International Affairs Committee at Medtech Europe, Europe's largest medical technology trade association. Further, he is a Member of the Board of Directors for the U.S.-Russia Business Council and is Chair of the Executive Council on Diplomacy. He sits on the Board of the Washington Export Council (Washington, D.C.), the Board of Advisers of the Washington International Business Council. He is also a member of the National Academy of Sciences/Institute of Medicine (IOM)'s Forum on Public-Private Partnerships for Global Health. In addition, Dr. Gunn serves on the Advisory Board of the University of Minnesota, Carlson Business School's, Carlson Global Institute. Dr. Gunn speaks Swedish, French and Russian and is a Vicennial Silver Medalist. He received his B.A. from University of San Francisco. He received his Ph.D. in International Relations from the London School of Economics in 1992.

Alan Knight, OBE, has over 25 years' experience of working with global companies and governments on sustainability. He joined the world's largest Steel company ArcelorMittal in 2014 as their General Manager for Sustainable development and Corporate Responsibility and, since then, has helped develop a sustainability framework ranging from products to process. He is Co-chairman of ResponsibleSteel and sits on the steering board of the Initiative for Responsible Mining. Mr. Knight created and chaired the

Ebola Private Sector Mobilisation Group, which was a collaboration of over 100 companies sharing best practice and coordinating the corporate response to Ebola in West Africa. For this he was made a Clinton Global Citizen honouree in 2015. He is now replicating the model for COVID-19. Previous to that, he was Sustainability Director for Business and the Community (BITC) where he oversaw all their Corporate Sustainability Programmes. He advised the Virgin Group on sustainable development for seven years. Previously he has worked with global companies as diverse as B&Q where he led their entire CSR and Sustainability programme for 10 years. He was instrumental in founding and developing the Forest Stewardship Council. He held similar roles in the Parent company Kingfisher and SABMiller, the multibillion brewery company. For nine years he was a commissioner with the Sustainable Development Commission and he introduced the concept of "choice editing" into the product policy debate. He is a Senior Associate of the Cambridge Programme for Sustainability Leadership. He was awarded the OBE in June 1998, in 2005 the US-based Rainforest Alliance presented him with a lifelong award and in 2013 he was made an Honorary Fellow of the Society for the Environment.

Frederik Kristensen, MD, MPH has been the Deputy CEO of the Coalition for Epidemic Preparedness Innovations (CEPI) since January 2017. Before joining CEPI he was a senior advisor on innovation at the World Health Organization in Geneva, in the Family, Women's and Children's Health Cluster. Dr. Kristensen is a healthcare executive with previous experience from the Norwegian Development Agency, hospital management and the pharmaceutical industry. He has started and run successful companies in the areas of health economics and decision support. At the start of his career he worked as a general practitioner in rural settings. He is an MD from the Universities of Oslo, Norway and Newcastle-upon-Tyne, UK, with a MPH/MBA degree from the University of California, Berkeley.

Ambassador John E. Lange, M.S., J.D., Senior Fellow, Global Health Diplomacy, serves as the UN Foundation's primary focal point for global health diplomacy activities and its wide-ranging work with the World Health Organization. He chairs the Leadership Team of the Measles & Rubella Initiative and earlier served as Co-Chair of the Global Polio Eradication Initiative's Polio Partners Group. Prior to joining the Foundation in July 2013, he spent four years at the Bill & Melinda Gates Foundation engaging in high-level global health advocacy with international organizations and African governments. Ambassador Lange had a distinguished 28-year career in the Foreign Service at the U.S. Department of State, where he was a pioneer in the field of global health diplomacy. He served as the Special Representative on Avian and Pandemic Influenza; Deputy Inspector General; Deputy U.S. Global AIDS Coordinator at the inception of the President's Emergency Plan for AIDS Relief; and U.S. Ambassador to Botswana (1999-2002), where HIV/AIDS was his signature issue. He led the U.S. Embassy in Dar es Salaam, Tanzania, as Chargé d'Affaires during the August 7, 1998, terrorist bombing, for which he received the State Department's Distinguished Honor Award for skilled leadership and extraordinary courage. From 1991 to 1995 at the U.S. Mission to the UN in Geneva, he managed humanitarian and refugee assistance channeled through international organizations. He also had tours of duty in the State Department Bureaus of African Affairs, Western Hemisphere Affairs and Management in Washington and at U.S. Embassies in Togo, France and Mexico. Prior to joining the diplomatic service in 1981, he worked for five years at the United Nations Association of the USA in New York. Lange is the author of a case study on pandemic influenza negotiations, has delivered numerous lectures and writes a blog on global health issues, and has served on global health and security committees of the U.S. National Academies of Sciences, Engineering and Medicine. He has an M.S. degree from the National War College and J.D. and B.A. degrees from the University of Wisconsin-Madison. He was admitted to the bar in Wisconsin (1975) and New York (1979) and has studied at The Hague Academy of International Law. He speaks English and Spanish and has working proficiency in French.

Rebecca Martin, Ph.D., is the Director of the Center for Global Health (CGH) at the U.S. Centers for Disease Control and Prevention (CDC). Dr Martin has worked both domestically and internationally in immunization, HIV, and health system strengthening and now leads CDC's global efforts to protect and improve health globally through science, policy, partnership, and evidence-based public health action. Dr. Martin has over 18 years of experience working in international health. Since 1991, Dr. Martin has worked in the global health arena and has had CDC assignments in Kenya, Tanzania, and Denmark (2002-2011). She was detailed to the WHO African Regional Office from 2002-2006, based in Kenya as a senior epidemiologist in the inter-country immunization program office for eight east African countries. From 2006-2008, Dr. Martin served as Program Director for Strategic Information and Human Resources for Health with the CDC Country Office in Tanzania. She led and implemented studies, in partnership with the ministry of health, to measure and evaluate the HIV/AIDS epidemic and strengthen national capacity to respond. Between 2008 and 2011, Dr. Martin was detailed to the WHO European Regional Office as the Regional Advisor for Immunization where she spearheaded regional efforts to strengthen immunization and surveillance systems, provide evidence for the introduction of new vaccines, achieve the goal of measles and rubella elimination, and maintain the region's polio-free status. Most recently from 2012 to 2016, Dr. Martin served as the Director of the CGH Global Immunization Division, which leads CDC's global polio eradication efforts, accelerated disease control for vaccine-preventable diseases, introduction of new and underutilized vaccines, and the strengthening of immunization systems. Dr. Martin began her career with CDC in 1997 in the National Immunization Program, Epidemiology and Surveillance Division. Prior to joining CDC, she worked at the Maryland Department of Hygiene and Mental Health in Baltimore Maryland as the immunization program epidemiologist leading efforts to increase vaccination coverage, conducting outbreak investigations, coordinating the development and introduction of Maryland's immunization registry, and supporting the state's Vaccines for Children Program. Dr. Martin received her Doctorate of Philosophy from the Johns Hopkins Bloomberg School of Public Health in international health with a focus in infectious disease epidemiology. Over the past 15 years, she has collaborated with multilateral organizations and development partners and has worked closely with ministries of health and non-governmental organizations. She has co-authored manuscripts and developed strategic plans, normative guidance and guidelines on immunization strategies, vaccine-preventable diseases and surveillance methods for both immunization and HIV.

Judith Monroe, M.D., president and CEO of the CDC Foundation, has dedicated her career to protecting people and saving lives. She joined the CDC Foundation in February 2016 as president and CEO, following her role as a deputy director of CDC and director of CDC's Office of State, Tribal, Local and Territorial Support. In her work at the CDC Foundation, Dr. Monroe advances priority programs that improve the health of people around the world and prepare other nations to better prevent, detect and respond to dangerous health threats, including the current COVID-19 pandemic. During her tenure as the state health commissioner for Indiana she served as president of the Association of State and Territorial Health Officials through the H1N1 pandemic. Dr. Monroe currently serves on the board of directors for the Center for Global Health Innovation and for the Georgia Global Health Alliance, and is a member of the Milken Institute's Public Health Advisory Board. Additionally, she serves as a member of the World Health Organization Foundation's Advisory group, as well as many national advisory committees and boards. Dr. Monroe was recognized in 2019 with the American Public Health Association's Presidential Citation for her work to improve the health and well-being of people around the world, and for her commitment to the future of public health as a mentor to young physicians and public health students. She received her doctor of medicine from the University of Maryland and a bachelor's of science degree from Eastern Kentucky University. Dr. Monroe completed her residency in

family medicine at the University of Cincinnati, a rural faculty development fellowship through East Tennessee State University, and a mini-fellowship in obstetrics through the University of Wisconsin. She also participated in the State Health Leadership Initiative at Harvard University's Kennedy School of Government and received an honorary doctorate from Purdue University in Health and Human Services.

John Nkengasong, M.S., M.D., is Director of the Africa Centers for Disease Control and Prevention. Prior to his current position, he served as the acting deputy principal director of the Center for Global Health, United States Centers for Disease Control and Prevention (U.S. CDC), and Chief of the International Laboratory Branch, Division of Global HIV and TB, U.S. CDC. He has received numerous awards for his work, including the Sheppard Award and the William Watson Medal of Excellence, the highest recognition awarded by CDC. He is also recipient of the Knight of Honour Medal by the Government of Cote d'Ivoire, was knighted in 2017 as Officer of Loin by the President of Senegal, H.E. Macky Sall, and knighted in November 2018 by the government of Cameroon for his significant contributions to public health. He is an adjunct professor at the Emory University, School of Public Health in Atlanta, Georgia. He serves on several international advisory boards including the Coalition for Epidemic Preparedness Initiative (CEPI) and the International AIDS Vaccine Initiative (IAVI), among others. He has authored over 250 peer-review articles in international journals and published several book chapters. He received a Master's degree in Tropical Biomedical Science at the Institute of Tropical Medicine in Antwerp, Belgium and a Doctorate in Medical Sciences (Virology) from the University of Brussels, Belgium.

Michael Osterholm, Ph.D., M.P.H., is Regents Professor, McKnight Presidential Endowed Chair in Public Health, director of the Center for Infectious Disease Research and Policy (CIDRAP), Distinguished Teaching Professor in the Division of Environmental Health Sciences, School of Public Health, a professor in the Technological Leadership Institute, College of Science and Engineering, and an adjunct professor in the Medical School, all at the University of Minnesota. From June 2018 through May 2019, he served as a Science Envoy for Health Security on behalf of the US Department of State. He is also on the Board of Regents at Luther College in Decorah, Iowa. He is the author of the 2017 book, *Deadliest Enemy: Our War Against Killer Germs*, in which he not only details the most pressing infectious disease threats of our day but lays out a nine-point strategy on how to address them, with preventing a global flu pandemic at the top of the list. In addition, Dr. Osterholm is a member of the National Academy of Medicine (NAM) and the Council of Foreign Relations. In June 2005 Dr. Osterholm was appointed by Michael Leavitt, Secretary of the Department of Health and Human Services (HHS), to the newly established National Science Advisory Board on Biosecurity. In July 2008, he was named to the University of Minnesota Academic Health Center's Academy of Excellence in Health Research. In October 2008, he was appointed to the World Economic Forum Working Group on Pandemics. From 2001 through early 2005, Dr. Osterholm, in addition to his role at CIDRAP, served as a Special Advisor to then-HHS Secretary Tommy G. Thompson on issues related to bioterrorism and public health preparedness. He was also appointed to the Secretary's Advisory Council on Public Health Preparedness. On April 1, 2002, Dr. Osterholm was appointed by Thompson to be his representative on the interim management team to lead the Centers for Disease Control and Prevention (CDC). With the appointment of Dr. Julie Gerberding as director of the CDC on July 3, 2002, Dr. Osterholm was asked by Thompson to assist Dr. Gerberding on his behalf during the transition period. He filled that role through January 2003. Previously, Dr. Osterholm served for 24 years (1975-1999) in various roles at the Minnesota Department of Health (MDH), the last 15 as state epidemiologist and chief of the Acute Disease Epidemiology Section. While at the MDH, Osterholm and his team were leaders in the area of infectious disease epidemiology. He has

led numerous investigations of outbreaks of international importance, including foodborne diseases, the association of tampons and toxic shock syndrome (TSS), the transmission of hepatitis B in healthcare settings, and human immunodeficiency virus (HIV) infection in healthcare workers. In addition, his team conducted numerous studies regarding infectious diseases in child-care settings, vaccine-preventable diseases (particularly *Haemophilus influenzae* type b and hepatitis B), Lyme disease, and other emerging infections. They were also among the first to call attention to the changing epidemiology of foodborne diseases. Dr. Osterholm was the Principal Investigator and Director of the NIH-supported Minnesota Center of Excellence for Influenza Research and Surveillance (2007-2014) and chaired the Executive Committee of the Centers of Excellence Influenza Research and Surveillance network. Dr. Osterholm has been an international leader on the critical concern regarding our preparedness for an influenza pandemic. His invited papers in the journals *Foreign Affairs*, the *New England Journal of Medicine*, and *Nature* detail the threat of an influenza pandemic before the recent pandemic and the steps we must take to better prepare for such events. Dr. Osterholm has also been an international leader on the growing concern regarding the use of biological agents as catastrophic weapons targeting civilian populations. In that role, he served as a personal advisor to the late King Hussein of Jordan. Dr. Osterholm provides a comprehensive and pointed review of America's current state of preparedness for a bioterrorism attack in his New York Times best-selling book, *Living Terrors: What America Needs to Know to Survive the Coming Bioterrorist Catastrophe*. The author of more than 315 papers and abstracts, including 21 book chapters, Dr. Osterholm is a frequently invited guest lecturer on the topic of epidemiology of infectious diseases. He serves on the editorial boards of nine journals, including *Infection Control and Hospital Epidemiology* and *Microbial Drug Resistance: Mechanisms, Epidemiology and Disease*, and he is a reviewer for 24 additional journals, including the *New England Journal of Medicine*, the *Journal of the American Medical Association*, and *Science*. He is past president of the Council of State and Territorial Epidemiologists (CSTE) and has served on the CDC's National Center for Infectious Diseases Board of Scientific Counselors from 1992 to 1997. Dr. Osterholm served on the IOM Forum on Microbial Threats from 1994 through 2011. He has served on the IOM Committee on Emerging Microbial Threats to Health in the 21st Century and the IOM Committee on Food Safety, Production to Consumption, and he was a reviewer for the IOM Report on Chemical and Biological Terrorism. As a member of the American Society for Microbiology (ASM), Dr. Osterholm has served on the Committee on Biomedical Research of the Public and Scientific Affairs Board, the Task Force on Biological Weapons, and the Task Force on Antibiotic Resistance. He is a frequent consultant to the World Health Organization (WHO), the National Institutes of Health (NIH), the Food and Drug Administration (FDA), the Department of Defense, and the CDC. He is a fellow of the American College of Epidemiology and the Infectious Diseases Society of America (IDSA). Dr. Osterholm has received numerous honors for his work, including an honorary doctorate from Luther College; the Pump Handle Award, CSTE; the Charles C. Shepard Science Award, CDC; the Harvey W. Wiley Medal, FDA; the Squibb Award, IDSA; Distinguished University Teaching Professor, Environmental Health Sciences, School of Public Health, UMN; and the Wade Hampton Frost Leadership Award, American Public Health Association. He also has been the recipient of six major research awards from the NIH and the CDC.

Peter Sands, M.B.A., has been the Executive Director of The Global Fund to Fight AIDS, Tuberculosis and Malaria since March 2018. Since June 2015, Mr. Sands has been a Research Fellow at Harvard University, dividing his time between the Mossavar-Rahmani Center for Business and Government at Harvard

Kennedy School and the Harvard Global Health Institute. Mr. Sands was Group CEO of Standard Chartered PLC from November 2006 to June 2015, having joined the Board of Standard Chartered as Group CFO in May 2002. Prior to joining Standard Chartered, Mr. Sands was a Senior Partner at McKinsey & Co. Mr. Sands has served on various boards and commissions, including as Lead Non-Executive Director of the UK Department of Health, Director of the World Economic Forum/Davos, Member of the International Advisory Board of the Monetary Authority of Singapore, Member of the China People's Association for Friendship with Foreign People's Global CEO Council, and Co-Chair of the UK-India CEO Forum. Mr. Sands graduated from Oxford University with a First Class degree in Politics, Philosophy and Economics. He also received a Master in Public Administration from Harvard University, where he was a Harkness Fellow.

Andreas Seiter, MD is the Global Lead for Private Sector in the World Bank's Health, Nutrition and Population Global Practice. His role is to work with World Bank teams and clients to strengthen private sector participation in the pursuit of Universal Health Coverage. He joined the Bank in 2004 and has been working on projects in more than 30 countries in all regions. Before joining the World Bank, he was with Novartis, a leading pharmaceutical company, where he spent 18 years in various positions in medical affairs, marketing, global policy and communications. Andreas was trained as a physician.

Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer, is a visionary leader who inspires and drives transformational innovation to bring years of life and quality of life to millions of people around the world. Dr. Stoffels spearheads the Johnson & Johnson research and product pipeline by leading teams across all our sectors to set the companywide innovation agenda, discovering and developing transformational healthcare solutions. He also is responsible for the safety of all products of the Johnson & Johnson Family of Companies worldwide, and steers the company's global public health strategy to make innovative medicines and technologies accessible in the world's most vulnerable communities and resource-poor settings. Dr. Stoffels' commitment to fueling innovation and finding the best science, wherever it exists, is the driving force behind the launch of Johnson & Johnson Innovation in 2013, which he now leads to foster science and technology through strategic partnerships, licensing and acquisitions. Dr. Stoffels also oversees JJDC, the oldest corporate venture fund in the life science industry. Previously, in his role as Worldwide Chairman, Pharmaceuticals, Dr. Stoffels led the transformation of the pharmaceutical research and development pipeline for Janssen Pharmaceutical Companies of Johnson & Johnson, driving a fundamental shift in the R&D paradigm that is now a model in the industry for productivity and innovation. Under his leadership, Janssen rejuvenated its pipeline, launching multiple new medicines and making a difference for people all over the world. Prior to this, Dr. Stoffels held various R&D leadership roles within the pharmaceutical sector of Johnson & Johnson. He joined Johnson & Johnson in 2002 with the acquisition of Virco and Tibotec, where he was Chief Executive Officer of Virco and Chairman of Tibotec, and led the development of several breakthrough products for the treatment of HIV that helped to transform this devastating disease from a death sentence to a chronic and treatable condition. Dr. Stoffels studied Medicine at the University of Diepenbeek and the University of Antwerp in Belgium and Infectious Diseases and Tropical Medicine at the Institute of Tropical Medicine in Antwerp, Belgium. He began his career as a physician in Africa, focusing on HIV and tropical diseases research.

Jeffrey L. Sturchio, Ph.D., is CEO at Rabin Martin, a global health strategy consulting firm, and former President and CEO of the Global Health Council. Before joining the Council in 2009, Dr. Sturchio was vice president of Corporate Responsibility at Merck & Co. Inc., and president of The Merck Company

Foundation. He serves as chairman of the U. S. Corporate Council on Africa (CCA), the BroadReach Institute for Training and Education, and Friends of the Global Fight Against AIDS, TB and Malaria, and also serves on the boards of ACHAP and the Science History Institute. Dr. Sturchio is a visiting scholar at the Institute for Applied Economics, Global Health and the Study of Business Enterprise at The Johns Hopkins University; Senior Associate at the Center for Strategic and International Studies; a principal of the Modernizing Foreign Assistance Network; Fellow of the American Association for the Advancement of Science; a member of the Council on Foreign Relations and the Arthur W. Page Society; and an advisor to amfAR, the Global Health Group at the University of California San Francisco; Intrahealth International; and the Rutgers Global Health Institute. He received an A.B. in history from Princeton University and a Ph.D. in the history and sociology of science from the University of Pennsylvania. His publications include *The Road to Universal Health Coverage: Innovation, Equity, and the New Health Economy* (edited with I. Kickbusch and L. Galambos, Johns Hopkins University Press, 2019).

Elhadj As Sy, M.A., is the Secretary General of the IFRC. He began this leadership role on 1 August, 2014 and is based at the IFRC secretariat in Geneva, Switzerland. Mr. Sy has extensive experience in leadership roles in the humanitarian sector, having previously served at a senior level with UNICEF, UNAIDS, the Global Fund to Fight AIDS, Tuberculosis and Malaria, and other agencies for more than 25 years. Before joining the IFRC - the world's largest humanitarian network - Mr. Sy was UNICEF's Director of Partnerships and Resource Development in New York. He has also served as UNICEF Regional Director for Eastern and Southern Africa and Global Emergency Coordinator for the Horn of Africa. From 2005 to 2008, Mr. Sy was Director, HIV/AIDS Practice with the United Nations Development Programme in New York. Before that, he worked with the Global Fund to Fight AIDS, Tuberculosis and Malaria as its Africa Regional Director and later as Director of Operational Partnerships and Country Support in Geneva. Mr. Sy has also held the position of UNAIDS Representative in New York and Director of the New York Liaison Office. From 1988 to 1997, he served as Director of Health and Development Programmes with Environment and Development Action in the Third World in Dakar, Senegal. Mr. Sy holds a Bachelor's Degree in Arts and Human Sciences from the University of Dakar. He then pursued Master's studies in Arts and Germanistik at the University of Graz, and graduated from the Diplomatic Academy in Vienna. He was also awarded a post graduate diploma in Education from the Ecole normale superieure in Dakar. He speaks English, French and German and is a national of Senegal.

Victoria (Vicki) M. Weldon, M.D., M.P.H., FACOEM, is the Global Medical Director for ExxonMobil's Medicine and Occupational Health Department. She has held a wide range of positions during her 26 years of service with ExxonMobil. She has a strong interest in preventive medicine/public health and its application in the workplace. In partnership with Human Resources Benefits Design, Safety and the business lines she has helped to implement ExxonMobil's wellness initiative called Culture of Health in the US and multiple international locations. Additional areas of focus have been emergency response, fitness for duty, development of business service models for occupational health, global implementation and continuous improvement of IT platform for occupational health services, and managing effective interfaces for health and safety in a matrixed corporate environment. Her medical degree was obtained at the University of Missouri-Kansas City School of Medicine. She is board certified in Internal Medicine, achieved a Master's Degree in Public Health and is a fellow of the American College of Occupational and Environmental Medicine. She is a member of multiple professional and industry groups including IOGP/IPIECA Health Committee and a past board member of National Business Group for Health subcommittee on Health and Human Capital.

